Orbufox Easyhaler
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Orbufox Easyhaler, 160 micrograms/4.5 micrograms/inhalation, inhalation powder.
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each delivered dose (the dose that leaves the mouthpiece) contains: budesonide
160 micrograms/inhalation and formoterol fumarate dihydrate 4.5 micrograms/inhalation.
With the Easyhaler device the delivered dose (ex-actuator) contains similar quantity of active substance as the metered dose (ex-reservoir).
Excipients with known effect: Lactose monohydrate 3800 micrograms per delivered dose
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL form
Inhalation powder in a device metered inhaler (Easyhaler).
White to yellowish powder.
4. Clinical particulars
4.1 Therapeutic indications
Orbufox Easyhaler is indicated in adults 18 years of age and older only.
Asthma
Orbufox Easyhaler is indicated for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting β2-adrenoceptor agonist) is appropriate:
patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short‑acting β2-adrenoceptor agonists.
or
patients already adequately controlled on both inhaled corticosteroids and long‑acting β2-adrenoceptor agonists.
Chronic Obstructive Pulmonary Disease (COPD)
Orbufox Easyhaler is indicated for the symptomatic treatment of patients with COPD with FEV1 < 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy (see also section 4.4).
4.2 Posology and method of administration
Posology
Orbufox Easyhaler is indicated in adults 18 years of age and older only.
Orbufox Easyhaler is not indicated for use in children, 12 years of age and younger or adolescents, 13 to 17
years of age.
Asthma
Orbufox Easyhaler is not intended for the initial management of asthma. The dosage of the components of Orbufox Easyhaler is individual and should be adjusted to the severity of the disease. This should be considered not only when treatment with combination products is initiated but also when the maintenance dose is adjusted. If an individual patient should require a combination of doses other than those available in the combination inhaler, appropriate doses of β2-adrenoceptor agonists and/or corticosteroids by individual inhalers should be prescribed.
The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Patients should be regularly reassessed by their prescriber/healthcare provider so that the dosage of Orbufox Easyhaler remains optimal. When long‑term control of symptoms is maintained with the lowest recommended dosage, then the next step could include a test of inhaled corticosteroid alone.
For Orbufox Easyhaler there are two treatment approaches:
A. maintenance therapy: Orbufox Easyhaler is taken as regular maintenance treatment with a separate rapid‑acting bronchodilator as rescue.
B. maintenance and reliever therapy: Orbufox Easyhaler is taken as regular maintenance treatment and as needed in response to symptoms.
A. maintenance
therapy
Patients should be advised to
have their separate rapid‑acting bronchodilator available for
rescue use at all times.
Recommended doses:
Adults (18 years and older): 1-2 inhalations twice daily. Some patients may require up to a maximum of 4 inhalations twice daily.
In usual practice when control of symptoms is achieved with the twice daily regimen, titration to the lowest effective dose could include Orbufox Easyhaler given once daily, when in the opinion of the prescriber, a long‑acting bronchodilator would be required to maintain control.
Increasing use of a separate rapid-acting bronchodilator indicates a worsening of the underlying condition and warrants a reassessment of the asthma therapy.
B. maintenance
and reliever therapy
Patients take a daily maintenance
dose of Orbufox Easyhaler and in addition take Orbufox Easyhaler as
needed in response to symptoms. Patients should be advised to
always have Orbufox Easyhaler available for rescue use.
Maintenance and reliever therapy should especially be considered for patients with:
-
inadequate asthma control and in frequent need of reliever medication
-
asthma exacerbations in the past requiring medical intervention
Close monitoring for dose-related adverse effects is needed in patients who frequently take high numbers of Orbufox Easyhaler as-needed inhalations.
Recommended doses:
Adults (18 years and older): The recommended maintenance dose is 2 inhalations per day, given either as one inhalation in the morning and evening or as 2 inhalations in either the morning or evening. For some patients a maintenance dose of 2 inhalations twice daily may be appropriate. Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion.
A total daily dose of more than 8 inhalations is not normally needed; however, a total daily dose of up to 12 inhalations could be used for a limited period.Patients using more than 8 inhalations daily should be strongly recommended to seek medical advice. They should be reassessed and their maintenance therapy should be reconsidered.
For dosages which cannot be achieved with Orbufox Easyhaler, other strengths of budesonide/formoterol medicinal products are available.
COPD
Recommended doses:
Adults (18 years and older): 2 inhalations twice daily.
General information
Special patient groups:
There are no special dosing requirements for elderly patients. There are no data available for use of Orbufox Easyhaler in patients with hepatic or renal impairment. As budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver cirrhosis.
Paediatric population:
The safety and efficacy of Orbufox Easyhaler in children, 12 years and younger and adolescents, 13 to 17
years of age has not yet been established. No data are available.
This medicinal product is not recommended for use in children and adolescents under the age of 18 years.
Method of administration
For inhalation use
Instructions for correct use of Orbufox Easyhaler:
The inhaler is inspiratory flow-driven, which means that when the patient inhales through the mouthpiece, the substance will follow the inspired air into the airways.
Note: It is important to instruct the patient
-
To carefully read the instructions for use in the patient information leaflet which is packed together with each Orbufox Easyhaler.
-
To shake and actuate the inhaler prior to each inhalation.
-
To breathe in forcefully and deeply through the mouthpiece to ensure that an optimal dose is delivered to the lungs.
-
Never to breathe out through the mouthpiece as this will result in a reduction in the delivered dose. Should this happen the patient is instructed to tap the mouthpiece onto a table top or the palm of a hand to empty the powder, and then to repeat the dosing procedure.
-
Never to actuate the device more than once without inhalation of the powder. Should this happen the patient is instructed to tap the mouthpiece onto a table top or the palm of a hand to empty the powder, and then to repeat the dosing procedure.
-
To always replace the dust cap (and, if in use, close the protective cover) after use to prevent accidental actuation of the device (which could result in either overdosing or under dosing the patient when subsequently used).
-
To rinse the mouth out with water after inhaling the maintenance dose to minimise the risk of oropharyngeal thrush. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations.
-
To clean the mouthpiece with a dry cloth at regular intervals. Water should never be used for cleaning because the powder is sensitive to moisture.
-
To replace Orbufox Easyhaler when the counter reaches zero even though powder can still be observed within the inhaler.
4.3 Contraindications
Hypersensitivity to the active substances or to the excipient listed in section 6.1(lactose, which contains small amounts of milk protein).
4.4 Special warnings and precautions for use
It is recommended that the dose is tapered when the treatment is discontinued and should not be stopped abruptly.
If patients find the treatment ineffective, or exceed the highest recommended dose of Orbufox Easyhaler, medical attention must be sought (see section 4.2). Sudden and progressive deterioration in control of asthma or COPD is potentially life threatening and the patient should undergo urgent medical assessment. In this situation, consideration should be given to the need for increased therapy with corticosteroids, e.g. a course of oral corticosteroids, or antibiotic treatment if an infection is present.
Patients should be advised to have their rescue inhaler available at all times, either Orbufox Easyhaler(for asthma patients using Orbufox Easyhaleras maintenance and reliever therapy) or a separate rapid-acting bronchodilator (for all patients using Orbufox Easyhaleras maintenance therapy only).
Patients should be reminded to take their Orbufox Easyhaler maintenance dose as prescribed, even when asymptomatic.The prophylactic use of Orbufox Easyhaler, e.g. before exercise, has not been studied. The reliever inhalations of Orbufox Easyhaler should be taken in response to asthma symptoms but are not intended for regular prophylactic use, e.g. before exercise. For such use, a separate rapid‑acting bronchodilator should be considered.
Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of Orbufox Easyhaler. Regular review of patients as treatment is stepped down is important. The lowest effective dose of Orbufox Easyhaler should be used (see section 4.2).
Patients should not be initiated on Orbufox Easyhaler during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma.
Serious asthma-related adverse events and exacerbations may occur during treatment with Orbufox Easyhaler. Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation of Orbufox Easyhaler.
There are no clinical study data on budesonide/formoterol combination products available in COPD patients with a pre-bronchodilator FEV1 >50% predicted normal and with a post-bronchodilator FEV1 <70% predicted normal (see section 5.1).
As with other inhalation therapy, paradoxical bronchospasm may occur, with an immediate increase in wheezing and shortness of breath after dosing. If the patient experiences paradoxical bronchospasm Orbufox Easyhaler should be discontinued immediately, the patient should be assessed and an alternative therapy instituted, if necessary. Paradoxical bronchospasm responds to a rapid‑acting inhaled bronchodilator and should be treated straightaway (see section 4.8).
Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. These effects are much less likely to occur with inhalation treatment than with oral corticosteroids. Possible systemic effects include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma, and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children) (see section 4.8).
Potential effects on bone density should be considered, particularly in patients on high doses for prolonged periods that have coexisting risk factors for osteoporosis. Long-term studies with inhaled budesonide in children at mean daily doses of 400 micrograms (metered dose) or in adults at daily doses of 800 micrograms (metered dose) have not shown any significant effects on bone mineral density. No information regarding the effect at higher doses is available.
If there is any reason to suppose that adrenal function is impaired from previous systemic steroid therapy, care should be taken when transferring patients to Orbufox Easyhaler therapy.
The benefits of inhaled budesonide therapy would normally minimise the need for oral steroids, but patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. Recovery may take a considerable amount of time after cessation of oral steroid therapy and hence oral steroid‑dependent patients transferred to inhaled budesonide may remain at risk from impaired adrenal function for some considerable time. In such circumstances HPA axis function should be monitored regularly.
Prolonged treatment with high doses of inhaled corticosteroids, particularly higher than recommended doses, may also result in clinically significant adrenal suppression. Therefore additional systemic corticosteroid cover should be considered during periods of stress such as severe infections or elective surgery. Rapid reduction in the dose of steroids can induce acute adrenal crisis. Symptoms and signs which might be seen in acute adrenal crisis may be somewhat vague but may include anorexia, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, decreased level of consciousness, seizures, hypotension and hypoglycaemia.
Treatment with supplementary systemic steroids or inhaled budesonide should not be stopped abruptly.
During transfer from oral therapy to Orbufox Easyhaler a generally lower systemic steroid action will be experienced which may result in the appearance of allergic or arthritic symptoms such as rhinitis, eczema and muscle and joint pain. Specific treatment should be initiated for these conditions. A general insufficient glucocorticosteroid effect should be suspected if, in rare cases, symptoms such as tiredness, headache, nausea and vomiting should occur. In these cases a temporary increase in the dose of oral glucocorticosteroids is sometimes necessary.
To minimise the risk of oropharyngeal candida infection (see section 4.8), the patient should be instructed to rinse their mouth out with water after inhaling the maintenance dose. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations.
Concomitant treatment with itraconazole, ritonavir or other potent CYP3A4 inhibitors should be avoided (see section 4.5). If this is not possible the time interval between administration of the interacting drugs should be as long as possible. In patients using potent CYP3A4 inhibitors, maintenance and reliever therapy approach is not recommended.
Orbufox Easyhaler should be administered with caution in patients with thyrotoxicosis, phaeochromocytoma, diabetes mellitus, untreated hypokalaemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm or other severe cardiovascular disorders, such as ischaemic heart disease, tachyarrhythmias or severe heart failure.
Caution should be observed when treating patients with prolongation of the QTc‑interval. Formoterol itself may induce prolongation of the QTc‑interval.
The need for, and dose of inhaled corticosteroids should be re-evaluated in patients with active or quiescent pulmonary tuberculosis, fungal and viral infections in the airways.
Potentially serious hypokalaemia may result from high doses of β2-adrenoceptor agonists. Concomitant treatment of β2-adrenoceptor agonists with drugs which can induce hypokalaemia or potentiate a hypokalaemic effect, e.g. xanthine-derivatives, steroids and diuretics, may add to a possible hypokalaemic effect of the β2-adrenoceptor agonist. Particular caution is recommended in unstable asthma with variable use of rescue bronchodilators, in acute severe asthma as the associated risk may be augmented by hypoxia and in other conditions when the likelihood for hypokalaemia is increased. It is recommended that serum potassium levels are monitored during these circumstances.
As for all β2-adrenoceptor agonists, additional blood glucose controls should be considered in diabetic patients.
Pneumonia in patients with COPD
An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids. There is some evidence of an increased risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all studies.
There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk among inhaled corticosteroid products.
Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations.
Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index (BMI) and severe COPD.
Orbufox Easyhaler contains approx. 4 mg of lactose per inhalation. This amount does not normally cause problems in lactose intolerant people. The excipient lactose contains small amounts of milk proteins, which may cause allergic reactions.
It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be re-evaluated with the aim of reducing the dose of inhaled corticosteroid to the lowest dose at which effective control of asthma is maintained, if possible. The benefits of the corticosteroid therapy and the possible risks of growth suppression must be carefully weighed. In addition consideration should be given to referring the patient to a paediatric respiratory specialist.
Limited data from long-term studies suggest that most children and adolescents treated with inhaled budesonide will ultimately achieve their adult target height. However, an initial small but transient reduction in growth (approximately 1 cm) has been observed. This generally occurs within the first year of treatment.
4.5 Interaction with other medicinal products and other forms of interaction
Pharmacokinetic interactions
Potent inhibitors of CYP3A4 (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and HIV protease inhibitors) are likely to markedly increase plasma levels of budesonide and concomitant use should be avoided. If this is not possible the time interval between administration of the inhibitor and budesonide should be as long as possible (see section 4.4). In patients using potent CYP3A4 inhibitors, maintenance and reliever therapy is not recommended.
The potent CYP3A4 inhibitor ketoconazole, 200 mg once daily, increased plasma levels of concomitantly orally administered budesonide (single dose of 3 mg) on average six-fold. When ketoconazole was administered 12 hours after budesonide the concentration was on average increased only three-fold showing that separation of the administration times can reduce the increase in plasma levels. Limited data about this interaction for high-dose inhaled budesonide indicates that marked increases in plasma levels (on average four fold) may occur if itraconazole, 200 mg once daily, is administered concomitantly with inhaled budesonide (single dose of 1000 µg).
Pharmacodynamic interactions
Beta‑adrenergic blockers can weaken or inhibit the effect of formoterol. Orbufox Easyhaler should therefore not be given together with beta-adrenergic blockers (including eye drops) unless there are compelling reasons.
Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine) and tricyclic antidepressants can prolong the QTc‑interval and increase the risk of ventricular arrhythmias.
In addition L‑Dopa, L‑thyroxine, oxytocin and alcohol can impair cardiac tolerance towards β2‑sympathomimetics.
Concomitant treatment with monoamine oxidase inhibitors including agents with similar properties such as furazolidone and procarbazine may precipitate hypertensive reactions.
There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons.
Concomitant use of other beta-adrenergic drugs or anticholinergic drugs can have a potentially additive bronchodilating effect.
Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glycosides.
Budesonide and formoterol have not been observed to interact with any other drugs used in the treatment of asthma.
Paediatric populations
Interaction studies have only been performed in adults.
4.6 Fertility, pregnancy and lactation
Pregnancy
For Orbufox Easyhaler or the concomitant treatment with formoterol and budesonide, no clinical data on exposed pregnancies are available. Data from an embryo-fetal development study in the rat showed no evidence of any additional effect from the combination.
There are no adequate data from use of formoterol in pregnant women. In animal studies formoterol has caused adverse effects in reproduction studies at very high systemic exposure levels (see section 5.3).
Data on approximately 2000 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide. In animal studies glucocorticosteroids have been shown to induce malformations (see section 5.3). This is not likely to be relevant for humans given recommended doses.
Animal studies have also identified an involvement of excess prenatal glucocorticoids in increased risks for intrauterine growth retardation, adult cardiovascular disease and permanent changes in glucocorticoid receptor density, neurotransmitter turnover and behaviour at exposures below the teratogenic dose range.
During pregnancy, Orbufox Easyhaler should only be used when the benefits outweigh the potential risks. The lowest effective dose of budesonide needed to maintain adequate asthma control should be used.
Breast-feeding
Budesonide is excreted in breast milk. However, at therapeutic doses no effects on the suckling child are anticipated. It is not known whether formoterol passes into human breast milk. In rats, small amounts of formoterol have been detected in maternal milk. Administration of Orbufox Easyhaler to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
Fertility
There is no data available on the potential effect of budesonide on fertility. Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure (see section 5.3).
4.7 Effects on ability to drive and use machines
Orbufox Easyhaler has no or negligible influence on the ability to drive and use machines.
Undesirable effects
Since Orbufox Easyhaler contains both budesonide and formoterol, the same pattern of undesirable effects as reported for these substances may occur. No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds. The most common drug related adverse reactions are pharmacologically predictable side-effects of β2 agonist therapy, such as tremor and palpitations. These tend to be mild and usually disappear within a few days of treatment.
Orbufox Easyhaler is not indicated in children and adolescents under the age of 18 years (see section 4.2).
Adverse reactions, which have been associated with budesonide or formoterol, are given below, listed by system organ class and frequency. Frequencies are defined as: very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1 000 to < 1/100), rare ( 1/10 000 to < 1/1 000) and very rare (< 1/10 000).
Table 1
|
SOC |
Frequency |
Adverse Drug Reaction |
|
Infections and infestations |
Common |
Candida infections in the oropharynx, pneumonia (in COPD patients) |
|
Immune system disorders |
Rare |
Immediate and delayed hypersensitivity reactions, e.g. exanthema, urticaria, pruritus, dermatitis, angioedema and anaphylactic reaction |
|
Endocrine disorders |
Very rare |
Cushing’s syndrome, adrenal suppression, growth retardation, decrease in bone mineral density |
|
Metabolism and nutrition disorders |
Rare |
Hypokalaemia |
|
Very rare |
Hyperglycaemia |
|
|
Psychiatric disorders |
Uncommon |
Aggression, psychomotor hyperactivity, anxiety, sleep disorders |
|
Very rare |
Depression, behavioural changes (predominantly in children) |
|
|
Nervous system disorders |
Common |
Headache, tremor |
|
Uncommon |
Dizziness |
|
|
Very rare |
Taste disturbances |
|
|
Eye disorders |
Very rare |
Cataract and glaucoma |
|
Cardiac disorders |
Common |
Palpitations |
|
Uncommon |
Tachycardia |
|
|
Rare |
Cardiac arrhythmias, e.g. atrial fibrillation, supraventricular tachycardia, extrasystoles |
|
|
Very rare |
Angina pectoris. Prolongation of QTc‑ interval |
|
|
Vascular disorders |
Very rare |
Variations in blood pressure |
|
Respiratory, thoracic and mediastinal disorders |
Common |
Mild irritation in the throat, coughing, hoarseness |
|
Rare |
Bronchospasm |
|
|
Gastrointestinal disorders |
Uncommon |
Nausea |
|
Skin and subcutaneous tissue disorders |
Uncommon |
Bruises |
|
Musculoskeletal and connective tissue disorders |
Uncommon |
Muscle cramps |
Candida infection in the oropharynx is due to drug deposition. Advising the patient to rinse the mouth out with water after each maintenance dose will minimise the risk. Oropharyngeal Candida infection usually responds to topical anti-fungal treatment without the need to discontinue the inhaled corticosteroid. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations.
As with other inhalation therapy, paradoxical bronchospasm may occur very rarely, affecting less than 1 in 10,000 people, with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid-acting inhaled bronchodilator and should be treated straightaway. Orbufox Easyhaler should be discontinued immediately, the patient should be assessed and an alternative therapy instituted if necessary (see section 4.4).
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing’s Syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. Increased susceptibility to infections and impairment of the ability to adapt to stress may also occur. Effects are probably dependent on dose, exposure time, concomitant and previous steroid exposure and individual sensitivity.
Treatment with β2 agonists may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
4.9 Overdose
An overdose of formoterol would likely lead to effects that are typical for β2-adrenoceptor agonists: tremor, headache, palpitations. Symptoms reported from isolated cases are tachycardia, hyperglycaemia, hypokalaemia, prolonged QTc‑interval, arrhythmia, nausea and vomiting. Supportive and symptomatic treatment may be indicated. A dose of 90 micrograms administered during three hours in patients with acute bronchial obstruction raised no safety concerns.
Acute overdosage with budesonide, even in excessive doses, is not expected to be a clinical problem. When used chronically in excessive doses, systemic glucocorticosteroid effects, such as hypercorticism and adrenal suppression, may appear.
If Orbufox Easyhaler therapy has to be withdrawn due to overdose of the formoterol component of the drug, provision of appropriate inhaled corticosteroid therapy must be considered.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Drugs for obstructive airway diseases: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics.
ATC‑code: R03AK07
Mechanisms of action and Pharmacodynamic effects
Orbufox Easyhaler contains formoterol and budesonide, which have different modes of action and show additive effects in terms of reduction of asthma exacerbations. The specific properties of budesonide and formoterol allow the combination to be used either as maintenance and reliever therapy or as maintenance treatment of asthma.
Budesonide
Budesonide is a glucocorticosteroid which when inhaled has a dose-dependent anti-inflammatory action in the airways, resulting in reduced symptoms and fewer asthma exacerbations. Inhaled budesonide has less severe adverse effects than systemic corticosteroids. The exact mechanism responsible for the anti-inflammatory effect of glucocorticosteroids is unknown.
Formoterol
Formoterol is a selective β2-adrenoceptor adrenergic agonist that when inhaled results in rapid and long-acting relaxation of bronchial smooth muscle in patients with reversible airways obstruction. The bronchodilating effect is dose-dependant, with an onset of effect within 1‑3 minutes. The duration of effect is at least 12 hours after a single dose.
Clinical efficacy and safety
Asthma
Clinical efficacy for budesonide/formoterol maintenance therapy
Clinical studies in adults have shown that the addition of formoterol to budesonide improved asthma symptoms and lung function, and reduced exacerbations. In two 12‑week studies the effect on lung function of budesonide/formoterol was equal to that of the free combination of budesonide and formoterol, and exceeded that of budesonide alone. All treatment arms used a short-acting β2-adrenoceptor agonist as needed. There was no sign of attenuation of the anti‑asthmatic effect over time.
Clinical efficacy for budesonide/formoterol maintenance and reliever therapy
A total of 12076 asthma patients were included in 5 double‑blind efficacy and safety studies (4447 were randomised to budesonide/formoterol maintenance and reliever therapy) for 6 or 12 months. Patients were required to be symptomatic despite use of inhaled glucocorticosteroids.
Budesonide/formoterol maintenance and reliever therapy provided statistically significant and clinically meaningful reductions in severe exacerbations for all comparisons in all 5 studies. This included a comparison with budesonide/formoterol at a higher maintenance dose with terbutaline as reliever (study 735) and budesonide/formoterol at the same maintenance dose with either formoterol or terbutaline as reliever (study 734) (Table 2). In Study 735, lung function, symptom control, and reliever use were similar in all treatment groups. In Study 734, symptoms and reliever use were reduced and lung function improved, compared with both comparator treatments. In the 5 studies combined, patients receiving budesonide/formoterol maintenance and reliever therapy used, on average, no reliever inhalations on 57% of treatment days. There was no sign of development of tolerance over time.
Table 2 Overview of severe exacerbations in clinical studies
|
Study No. Duration |
Treatment groups |
n |
Severe exacerbationsa |
|
|
Events |
Events/ patient‑year |
|||
|
Study 735 |
Budesonide/formoterol 160/4.5 µg bd + as needed |
1103 |
125 |
0.23b |
|
Budesonide/formoterol 320/9 µg bd + terbutaline 0.4 mg as needed |
1099 |
173 |
0.32 |
|
|
Salmeterol/fluticasone 2 x 25/125 µg bd + terbutaline 0.4 mg as needed |
1119 |
208 |
0.38 |
|
|
Study 734 |
Budesonide/formoterol 160/4.5 µg bd + as needed |
1107 |
194 |
0.19b |
|
Budesonide/formoterol 160/4.5 µg bd + formoterol 4.5 µg as needed |
1137 |
296 |
0.29 |
|
|
Budesonide/formoterol 160/4.5 µg bd + terbutaline 0.4 mg as needed |
1138 |
377 |
0.37 |
|
a Hospitalisation/emergency room treatment or treatment with oral steroids
b Reduction in exacerbation rate is statistically significant (P‑value <0.01) for both comparisons
In 2 other studies with patients seeking medical attention due to acute asthma symptoms, budesonide/formoterol provided rapid and effective relief of bronchoconstriction similar to salbutamol and formoterol.
COPD
In two 12‑month studies, the effect on lung function and the rate of exacerbation (defined as courses of oral steroids and/or course of antibiotics and/or hospitalisations) in patients with moderate to severe COPD was evaluated. The inclusion criteria for both studies was pre-bronchodilator FEV1<50% predicted normal. Median post-bronchodilator FEV1at inclusion in the trials was 42% predicted normal. The mean number of exacerbations per year (as defined above) was significantly reduced with budesonide/formoterol as compared with treatment with formoterol alone or placebo (mean rate 1.4 compared with 1.8‑1.9 in the placebo/formoterol group). The mean number of days on oral corticosteroids/patient during the 12 months was slightly reduced in the budesonide/formoterol group (7‑8 days/patient/year compared with 11‑12 and 9‑12 days in the placebo and formoterol groups, respectively). For changes in lung‑function parameters, such as FEV1, budesonide/formoterol was not superior to treatment with formoterol alone.
5.2 Pharmacokinetic properties
Absorption
Orbufox Easyhaler and Symbicort Turbuhaler fixed‑dose combination of budesonide and formoterol have been shown to be bioequivalent with regard to total systemic exposure and exposure via the lungs.
Symbicort Turbuhaler fixed‑dose combination of budesonide and formoterol, and the corresponding monoproducts have been shown to be bioequivalent with regard to systemic exposure of budesonide and formoterol, respectively. In spite of this, a small increase in cortisol suppression was seen after administration of the fixed‑dose combination compared to the monoproducts. The difference is considered not to have an impact on clinical safety.
There was no evidence of pharmacokinetic interactions between budesonide and formoterol.
Pharmacokinetic parameters for the respective substances were comparable after the administration of budesonide and formoterol as monoproducts or as the fixed‑dose combination. For budesonide, AUC was slightly higher, rate of absorption more rapid and maximal plasma concentration higher after administration of the fixed combination. For formoterol, maximal plasma concentration was similar after administration of the fixed combination. Inhaled budesonide is rapidly absorbed and the maximum plasma concentration is reached within 30 minutes after inhalation. In studies, mean lung deposition of budesonide after inhalation via the powder inhaler ranged from 32% to 44% of the delivered dose. The systemic bioavailability is approximately 49% of the delivered dose. In children 6‑16 years of age the lung deposition falls in the same range as in adults for the same given dose. The resulting plasma concentrations were not determined.
Inhaled formoterol is rapidly absorbed and the maximum plasma concentration is reached within 10 minutes after inhalation. In studies the mean lung deposition of formoterol after inhalation via the powder inhaler ranged from 28% to 49% of the delivered dose. The systemic bioavailability is about 61% of the delivered dose.
Distribution and biotransformation
Plasma protein binding is approximately 50% for formoterol and 90% for budesonide. Volume of distribution is about 4 l/kg for formoterol and 3 l/kg for budesonide. Formoterol is inactivated via conjugation reactions (active O‑demethylated and deformylated metabolites are formed, but they are seen mainly as inactivated conjugates). Budesonide undergoes an extensive degree (approximately 90%) of biotransformation on first passage through the liver to metabolites of low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6‑beta‑hydroxy‑budesonide and 16‑alfa‑hydroxy‑prednisolone, is less than 1% of that of budesonide. There are no indications of any metabolic interactions or any displacement reactions between formoterol and budesonide.
Elimination
The major part of a dose of formoterol is transformed by liver metabolism followed by renal elimination. After inhalation, 8% to 13% of the delivered dose of formoterol is excreted unmetabolised in the urine. Formoterol has a high systemic clearance (approximately 1.4 l/min) and the terminal elimination half‑life averages 17 hours.
Budesonide is eliminated via metabolism mainly catalysed by the enzyme CYP3A4. The metabolites of budesonide are eliminated in urine as such or in conjugated form. Only negligible amounts of unchanged budesonide have been detected in the urine. Budesonide has a high systemic clearance (approximately 1.2 l/min) and the plasma elimination half‑life after i.v. dosing averages 4 hours.
The pharmacokinetics of formoterol in children have not been studied. The pharmacokinetics of budesonide or formoterol in patients with renal failure are unknown. The exposure of budesonide and formoterol may be increased in patients with liver disease.
Linearity/non-linearity
Systemic exposure for both budesonide and formoterol correlates in a linear fashion to administered dose.
5.3 Preclinical safety data
The toxicity observed in animal studies with budesonide and formoterol, given in combination or separately, were effects associated with exaggerated pharmacological activity.
In animal reproduction studies, corticosteroids such as budesonide have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results do not seem to be relevant in humans at the recommended doses. Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure and implantation losses as well as decreased early postnatal survival and birth weight at considerably higher systemic exposures than those reached during clinical use. However, these animal experimental results do not seem to be relevant in humans.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose monohydrate (which contains milk proteins).
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
As packaged for sale: 2 years.
After first opening the laminate bag: 4 months. Do not store above 25°C and protect from moisture.
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
For storage conditions after first opening of the medicinal product, see section 6.3.
Nature and contents of container
The multidose powder inhaler consists of seven plastic parts and a stainless steel spring. The plastic materials of the inhaler are: polybutylene terepthalate, low density polyethylene, polycarbonate, styrene butadiene, polypropylene. The inhaler is sealed in a laminate bag and packed with or without a protective cover (polypropylene and thermoplastic elastomer) in a cardboard box.
Packages:
Orbufox Easyhaler 160/4.5 micrograms/inhalation, inhalation powder:
60 doses
60 doses + protective cover
120 doses
120 doses + protective cover
180 doses (3 x 60 doses)
360 doses (3 x 120 doses)
Not all packs may be marketed.
6.6 Special precautions for disposal
No special requirements
7. MARKETING AUTHORISATION HOLDER
Orion Corporation
Orionintie 1
FI-02200 Espoo
Finland
8. MARKETING AUTHORISATION NUMBER(S)
[To be completed nationally]
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT
7 November 2016
13